Evidence map›Paper›PMID 34568060›Full record

ArticleFrontiers in oncology2021

Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia.

Valerio Guarente, Giovanni Martino, Erica Dorillo, Filomena De Falco, Chiara Rompietti, Daniele Sorcini, Mariangela Brogna, Valeria Cardinali, Stefano Ascani, Andrea Marra and 1 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Valerio GuarenteInstitute of Hematology-Centro di Ricerca Emato-Oncologica (CREO), Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Giovanni MartinoInstitute of Hematology-Centro di Ricerca Emato-Oncologica (CREO), Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Erica DorilloInstitute of Hematology-Centro di Ricerca Emato-Oncologica (CREO), Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Filomena De FalcoInstitute of Hematology-Centro di Ricerca Emato-Oncologica (CREO), Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Chiara RompiettiInstitute of Hematology-Centro di Ricerca Emato-Oncologica (CREO), Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Daniele SorciniInstitute of Hematology-Centro di Ricerca Emato-Oncologica (CREO), Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Mariangela BrognaInstitute of Hematology-Centro di Ricerca Emato-Oncologica (CREO), Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Valeria CardinaliInstitute of Hematology-Centro di Ricerca Emato-Oncologica (CREO), Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Stefano AscaniInstitute of Hematology-Centro di Ricerca Emato-Oncologica (CREO), Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Andrea MarraInstitute of Hematology-Centro di Ricerca Emato-Oncologica (CREO), Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Paolo SportolettiInstitute of Hematology-Centro di Ricerca Emato-Oncologica (CREO), Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
University of Perugia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 57-year-old man affected by high-risk progressive chronic lymphocytic leukemia (CLL), primary resistant to first-line chemoimmunotherapy, developed a type A lymphomatoid papulosis (LyP) during a second progression of CLL. The two blood tumor entities were clonally unrelated. LyP presented with a diffuse (>90% body surface area) cutaneous rash and was characterized by intensely pruriginous dusky nodules (n = 10) and red flat-topped papules (n = 60). No response to topical corticosteroids and psoralen plus ultraviolet A (PUVA) phototherapy was observed. In order to effectively treat progressive

Indexed as

chronic lymphocytic leukemialymphomatoid papulosis (LyP)lymphomatoid papulosis treatmentT-cell lymphomavenetoclax (BCL2 inhibitor)

Identifiers

PMID34568060
PMCPMC8459905
OpenAlexW3199423782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.